Evaluating a Next Generation LBP Therapy for Patients with Dravet and ALS

Time: 12:45 pm
day: Day One Track A AM


  • IrisRx – a platform for mechanistic based LBP drug development
  • Rational selection of BL-001 strains in drug-resistant epilepsy and ALS
  • Results of a pilot study with BL-001 in healthy volunteers